Clinical Trial Update: A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)

View source ↗

Summary

A Roche-sponsored clinical trial evaluating risdiplam for spinal muscular atrophy types I and II is listed as NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• EVRYSDI (risdiplam)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Spinal Muscle Atrophy | Status: NOT_YET_RECRUITING